Author

William Sandborn

HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS
HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS

William Sandborn  et al.

HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY
HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY

William Sandborn  et al.

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2
A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

William Sandborn  et al.

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

William Sandborn  et al.

ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS
ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS

William Sandborn  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

William Sandborn  et al.

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

William Sandborn  et al.

CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

William Sandborn  et al.

PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH
PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH

William Sandborn  et al.

Item 61 - 69 / 69
1 2 3
4